Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase ...

Novo Nordisk has taken initiatives to accelerate target discovery by implementing AI/ML technologies into genetic and ...

Revenue for Madrigal’s Rezdiffra, already approved in the US, is expected to skyrocket over the coming decade.

Blockchain has numerous potential benefits for healthcare, which is the topic of episode three in the Blockchain in Scotland ...

Nicole Verdun, a highly respected individual in the cell and gene therapy space, was placed on administrative leave this week ...

The FDA has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a pre-exposure prophylaxis (PrEP) against ...

While the outlook for vaccines in the US looks bleak under Trump's administration, the UK is pressing ahead with securing its ...

Actio Biosciences has closed a Series B financing round, raising $66m for advancing the genetics-driven small molecule ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications ...

Draig Therapeutics has secured £107m ($140m) in an oversubscribed Series A financing round to treat major neuropsychiatric ...

Lynozyfic’s global sales are projected to reach $707 million by 2031.